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Viral vectors based on the adeno-associated virus (AAV) hold great
promise for in vivo gene transfer; several unknowns, however, still
limit the vectors’ broader and more efficient application. Here, we
report the results of a high-throughput, whole-genome siRNA screen-
ing aimed at identifying cellular factors regulating AAV transduction.
We identified 1,483 genes affecting vector efficiency more than 4-fold
and up to 50-fold, either negatively or positively. Most of these fac-
tors have not previously been associated to AAV infection. The most
effective siRNAs were independent from the virus serotype or
analyzed cell type and were equally evident for single-stranded
and self-complementary AAV vectors. A common characteristic of
the most effective siRNAs was the induction of cellular DNA dam-
age and activation of a cell cycle checkpoint. This information can
be exploited for the development of more efficient AAV-based
gene delivery procedures. Administration of the most effective
siRNAs identified by the screening to the liver significantly im-
proved in vivo AAV transduction efficiency.
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Viral vectors based on the adeno-associated virus (AAV) havereceived incremental attention over the past two decades as
effective tools for in vivo gene transfer. The vectors’ intrinsic
structural simplicity, lack of pathogenicity, low immunogenicity,
and ability to mediate long-term, episomal expression in non-
dividing cells in vitro and, most notably, postmitotic organs in vivo
are desirable characteristics for several gene therapy applications
(reviewed in ref. 1). Indeed, to date, over 90 clinical trials using
these vectors have been carried out (www.abedia.com/wiley/index.
html); the first commercial gene therapy product (Glybera) is an
AAV1 vector for the treatment of familial lipoprotein lipase
deficiency (2).
Despite these achievements, AAV vectors still display an un-
deniable number of limitations in terms of restricted cellular
permissivity and efficacy of transgene expression. Efficient trans-
duction in vivo is essentially limited to postmitotic cells [in partic-
ular, cardiomyocytes, neurons, retinal cells, and skeletal muscle
fibers (1)] and requires infection at a relatively high multiplicity
of infection; in addition, vector-driven gene expression is
achieved only after a relatively long lag period (3). These char-
acteristics are still incompletely understood in molecular terms
but certainly reside within the intrinsic biological properties of
target cells. This finding is also highlighted by the peculiar biology of
wild-type AAV, which, for the completion of its biological cycle,
requires cellular coinfection by adenovirus or other viruses that
modify the cellular environment of the target cells, rendering
them permissive for viral replication (4–6).
The efficient internalization of AAV vectors into different cell
types is mediated by the binding of virions to ubiquitously
expressed cell surface receptors (7, 8); tropism is further ex-
panded by the availability of over a dozen different viral serotypes
(9–12). Restriction of permissivity, however, mainly occurs at the
postentry level, where multiple barriers constrain vector trans-
duction. These include entrapment of virions inside the endo-
somal/lysosomal compartments, impaired nuclear translocation,
and uncoating, inefficient single-stranded (ss) to double-stranded
(ds) genome conversion and poor stabilization of newly formed
viral dsDNA as single or concatemeric circular episomes (13–18).
A better understanding of the cellular factors responsible for
these molecular events appears crucial for the development of
vectors capable of overcoming the limitations witnessed by a
number of clinical applications (19–21).
Long-standing evidence hints at a specific connection between
cellular stress and permissivity to AAV transduction. In partic-
ular, cell treatment with a variety of genotoxic agents or viral
coinfection are major determinants of both wild-type AAV per-
missivity and efficiency of recombinant AAV vectors (reviewed in
ref. 22). The molecular correlates of these observations, how-
ever, still remain vague.
Previous evidence had indicated that the conversion of the
AAV ssDNA genome into a dsDNA form is a rate-limiting step
for the onset of AAV-mediated transgene expression (13, 23).
This has prompted the development of the self-complementary
AAV (scAAV) vector technology, by which small AAV genomes,
less than half the size of wild-type AAV, are efficiently packaged
as dimeric inverted repeats (24).
To better understand the molecular determinants of AAV vec-
tor transduction and thus increase and expand their efficacy, here
we report the results of a whole-genome, high-throughput siRNA
screening, in which we assessed the effect of the knockdown of
18,120 human genes on AAV transduction. The siRNA technology
represents a powerful tool to systematically investigate the role of
cellular determinants on a given biological event and has already
been applied to identify the host proteins needed for permissivity
of different viruses, most notably HIV-1 (25, 26), hepatitis C virus
(27), West Nile virus (28), and influenza virus (29).
By our screening, we identified 1,483 cellular factors signifi-
cantly affecting, either positively or negatively, AAV vector ef-
ficiency. A common characteristic of the most effective siRNAs
was the induction of cellular DNA damage. These findings are
relevant for the development of innovative strategies to improve
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the efficiency of AAV transduction, either through the devel-
opment of small molecules against the factors restricting AAV
transduction or through their transient down-regulation. Indeed,
the administration to the liver of the most effective siRNAs
identified in the screening significantly improved AAV trans-
duction efficiency.
Results
Genome-Wide RNAi Screening for AAV Permissivity. To systematically
identify host cell factors that modulate the different steps of AAV
transduction, we performed a high-throughput RNAi screening
using a genome-wide siRNA library (18,120 human gene targets;
pools of four siRNAs per gene arrayed on 384-well plates; Fig. 1A).
HeLa cells were transfected with the siRNA library (>95% trans-
fection efficiency; Fig. S1A) and 48 h later were infected with a
recombinant ssAAV2 vector encoding the firefly luciferase reporter
gene [ssAAV2-Luciferase; multiplicity of infection (moi): 2,500 viral
genomes (vg)/cell]. Serotype 2 is the most common and more ex-
tensively studied AAV serotype. Luciferase activity was used to
assess ssAAV2 transduction, and cell viability was monitored in
parallel by using Alamar Blue. The screening was performed in
duplicate; the replicates showed very good reproducibility [Spear-
man r = 0.95 (Fig. S1B); Fig. S1C shows controls].
This unbiased screening approach identified 1,483 genes af-
fecting ssAAV2 transduction by more than fourfold (178 genes
by more than eightfold). Of these, siRNAs targeting 968 genes
increased ssAAV2 transduction (inhibitory genes; red in Fig. 1 B
and C and Dataset S1), whereas siRNAs targeting 515 genes
decreased ssAAV2 transduction by more than fourfold (required
genes; blue in Fig. 1 B and C and Dataset S1). Of note, most of
these genes have not been previously associated with ssAAV2
transduction. siRNA pools decreasing cell viability to less than
75% were considered toxic and were excluded from further analysis
[256 of 18,120 siRNA pools (i.e., 1.4%); open circles in Fig. 1B and
Dataset S1]; these included siRNAs against well known, essential
genes [e.g., ubiquitin B and C, COPB1/2, polo-like kinase 1
(PLK1)]. Remarkably, the 10 top-scoring siRNA pools increased or
decreased ssAAV2 transduction by as much as 50- and 10-fold,
respectively (Fig. 1D and Table S1).
We wanted to confirm the results from the primary screening
and discriminate between siRNAs targeting genes with a specific
effect on ssAAV2 transduction from those with general effects
on gene expression and/or protein production, which might
thus indirectly affect AAV-encoded luciferase expression. We
therefore performed a high-content fluorescence microscopy
secondary screening using the siRNAs against the 1,483 genes
that affected ssAAV2 transduction by more than fourfold in the
primary screening. HeLa cells stably expressing EGFP (HeLa-
EGFP) were transfected with the siRNAs of interest and trans-
duced, 48 h later, with a ssAAV2 vector encoding the red fluo-
rescent protein DsRed (ssAAV2-DsRed; moi: 2,500 vg/cell)
(Fig. 2A). To eliminate any bias in the regulation of transgene
expression, EGFP and DsRed reporter genes were expressed
from analogous expression cassettes, driven by the cytomegalo-
virus immediate early (CMV IE) promoter.
From the 1,483 siRNA pools tested, we selected those that
increased or decreased the percentage of DsRed-positive cells by
Fig. 1. Genome-wide RNAi screening identifies genes regulating AAV
transduction. (A) Primary screening workflow. (B) Luciferase activity and cell
viability after treatment with the siRNA library targeting 18,120 genes.
siRNA pools increasing or decreasing AAV transduction by more than four-
fold are highlighted in red and blue, respectively; siRNA pools decreasing cell
viability to less than 75% (open circles) were excluded from further analysis.
(C) Effect of siRNAs on AAV transduction; 968 genes were identified as
negative regulators of AAV transduction and 515 as positive regulators.
(D) Effect of the 10 most effective siRNA pools in increasing and decreasing
AAV transduction. Numbers above and below bars represent fold changes.
Averages from the two screening replicates are shown in B–D.
Fig. 2. Effect of siRNAs on AAV transduction is not cell-type specific and is
independent of vector serotype. (A) Schematic of secondary high-content
screening. (B) Percentage of DsRed- and EGFP-positive cells after treatment
with siRNAs against the 1,483 genes selected from the primary screening.
siRNA pools increasing or decreasing AAV transduction by more than two-
fold are highlighted in red and blue, respectively; siRNA pools decreasing
EGFP expression to less than 75% are shown in black. (C) Representative
images of HeLa-EGFP cells treated with selected siRNA pools and transduced
with ssAAV2-DsRed. (Scale bar: 100 μm.) (D–I) Effect of the 10 siRNA pools
that increased AAV transduction more efficiently in the primary screening, in
three different cell lines [HeLa (D), MRC5 (E), and U2OS (F)] and using three
different AAV serotypes in HeLa cells [AAV5 (G), AAV6 (H), and AAV9 (I)];
results are shown as means ± SEM [n = 4 (D–F); n = 3 (G–I)]. *P < 0.05, **P <
0.01, and ***P < 0.001 of individual datasets vs. control.
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more than twofold, compared with control siRNA (red and blue,
respectively, in Fig. 2B; Dataset S2). The siRNAs that resulted in
less than 75% EGFP-positive cells were removed from our can-
didate list (95 of 1,483 siRNA pools; black in Fig. 2B; Dataset S2).
This two-step screening procedure resulted in a final candidate
list composed of 710 genes inhibitory of, and 414 genes required
for, efficient ssAAV2 transduction. Representative images of
cells treated with the control siRNA or siRNAs that decrease
[against chromodomain protein, Y-linked, 2A (CDY2A); and
B melanoma antigen family, member 2 (BAGE2)] or increase
[against SET domain-containing (lysine methyltransferase) 8
(SETD8); caspase 8-associated protein 2 (CASP8AP2); and SRY
(sex-determining region Y)-box 15 (SOX15)] ssAAV2 transduc-
tion are shown in Fig. 2C; results for the top 10 genes are shown
in Fig. S2. Gene-ontology analysis of the genes inhibiting ssAAV2
transduction revealed a clear overrepresentation of genes related
to cell cycle, cellular growth and proliferation, and DNA recom-
bination and repair, whereas in the subset of genes required for
transduction an overrepresentation of genes involved in gene ex-
pression, intracellular trafficking and transcription was observed
(Fig. S3 A and B).
The use of pooled siRNA libraries (here four siRNAs per
gene) decreases the likelihood of off-target effects by lowering
the effective concentration of each individual siRNA. To test the
efficacy of the individual siRNAs in each pool, we deconvoluted
the siRNA pools corresponding to the 108 top candidate genes
of the primary screening (68 inhibitory genes and 40 required
genes) and assessed the effect of each siRNA on ssAAV2
transduction (432 siRNAs total). Overall, 78 of the 108 tested
genes (72%) were validated, each one with at least two siRNAs
exhibiting a phenotype matching that of the corresponding pool
(Fig. S4). The top 10 genes increasing ssAAV2 transduction were
all successfully validated using this criterion (Fig. S4).
Given our interest in improving AAV2 transduction for gene
transfer applications, we concentrated on the top 10 genes that,
once silenced, increase ssAAV2 efficiency (i.e., act as inhibitors
of viral transduction). The effect of these genes was not re-
stricted to HeLa cells but could also be observed in two other
human cell lines (U2OS and MRC5; Fig. 2 D–F). The effect of
the top 10 most effective siRNAs was also observed in HeLa cell
transduction by other AAV serotypes (AAV5, AAV6, AAV9;
Fig. 2 G–I). Efficient knockdown of the top 10-selected genes
was verified (Fig. S5). Of note, silencing of these genes also
increased transduction of ΔVP1-ssAAV2 particles, which are
strongly impaired in intracellular trafficking (30). However,
transduction was significantly lower than that of wild-type AAV
vectors (Fig. S6; compare Fig. 2D). Together, these findings in-
dicate that the identified genes are broad regulators of ssAAV
transduction, irrespective of target cells or vector serotype.
A Largely Overlapping Set of Host Factors Regulates both ssAAV and
scAAV Transduction. scAAV vectors have gained increased at-
tention because of their higher efficiency of transduction of
several tissues in vivo. We performed an additional high-content
microscopy secondary screening to compare the cellular factors
required for transduction by ssAAV and scAAV vectors. Cells
were transfected with siRNAs targeting the 1,483 genes selected
from the primary screening, and, 48 h after cells were transduced
with an scAAV2 vector encoding EGFP (scAAV2-EGFP; moi:
2,500 vg/cell) (Fig. 3A). There was remarkable correlation be-
tween the ss- and scAAV2 results (Spearman r = 0.84; Fig. 3B
and Dataset S3), indicating that most of the identified effects
were common for both vectors. Notwithstanding this commu-
nality, some siRNAs showed a differential effect (130 genes
showing a >twofold difference in their effect on ss- compared
with scAAV vectors; 8.8%). Among others, the siRNAs against
P2RX7 preferentially increased ssAAV transduction, whereas
the siRNAs against SAE1 preferentially increased scAAV
transduction (Fig. 3 B and C and Dataset S3). Of note, the
top 10 siRNA pools described above for ssAAV2 vectors in-
creased transduction of scAAV2 to a similar extent (Fig. 3D
and Dataset S3).
Cellular DNA Damage Is a Strong Determinant of AAV Transduction.
Long-standing evidence indicates that genotoxic damage is a
major determinant of cellular permissivity to AAV (4, 5). In
addition, AAV transduction is inhibited by proteins of the DNA-
damage response (DDR) (31), in both cell culture (32) and in vivo
(33). Finally, among the genes inhibitory to ssAAV2 transduction in
our primary screening, there was a clear overrepresentation of
functional gene categories related to cellular growth and pro-
liferation, cell cycle, and DNA repair (Fig. S3). These observations
prompted us to investigate the effect of the siRNAs identified to
regulate AAV permissivity on cellular DNA damage, in the ab-
sence of viral infection.
We performed an additional image-based screening to in-
vestigate the effect of the 968 siRNA pools increasing ssAAV
transduction and of the 515 siRNA pools decreasing it, on the
phosphorylation of histone H2AX at serine 139 (ɣ-H2AX), a
hallmark of cellular DNA damage. We found that 17 of 968 and
2 of 515 siRNAs also determined the formation of ɣ-H2AX foci
(P < 0.05; Fig. 4A and Dataset S4). Even more remarkably, if one
considers the top 10 most effective and the top 10 least effective
siRNAs, 5 of 10 and 0 of 10, respectively, also determine DNA
damage (P < 0.01; Fig. 4B). Down-regulation of all these genes
also induced a remarkable aberration of the cell cycle profile,
suggesting cell cycle checkpoint activation (Fig. 4C). In a consistent
manner, the siRNAs against these five genes also induced phos-
phorylation of CHK1; in the case of SETD8 and CASP8AP2,
phosphorylation of ATM was also observed (Fig. 4D). Hydroxyurea
(HU) was used a positive control in these experiments.
These results indicate that several of the siRNAs inducing
cellular permissivity to AAV also determine DNA damage. This
Fig. 3. Transduction by ssAAV and scAAV is controlled by an overlapping
set of host factors. (A) Schematic of ssAAV2-DsRed and scAAV2-EGFP.
(B) Analysis of cellular factors required for transduction by ssAAV and scAAV
vectors. siRNAs against the 1,483 genes selected from the primary screening
were tested. (C) Representative images of HeLa cells treated with control or
selected siRNAs (SETD8, P2RX7, and SAE1) and transduced with ssAAV2-
DsRed or scAAV2-EGFP. (Scale bar: 100 μm.) (D) Effect of top 10 siRNAs in-
creasing AAV transduction, selected based on the primary screening, on
ssAAV2-DsRed and scAAV2-EGFP transduction. Averages from the two
screening replicates are shown in B and D.
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conclusion is consistent with our previous observation showing
that DDR activation reduces binding of cellular DNA-damage
sensing proteins, including MRN (Mre11, Rad50, Nbs1) mem-
bers, to the incoming AAV genomes, thus facilitating their ss- to
dsDNA conversion (32, 33). We also analyzed the extent of ss- to
dsDNA conversion using a cellular system based on the visuali-
zation of dsDNA AAV genomes carrying multiple repeats of the
Lac operator sequence, in HeLa cells expressing a nuclear Lac
repressor (32). We found that all of the top 10 siRNAs increased
the percentage of cells carrying dsDNA AAV foci in the nucleus
(Fig. 4 E and F).
Transient Knockdown of the Identified Inhibitory Genes Boosts AAV
Transduction in Vivo. Finally, we wanted to assess whether
knockdown of the inhibitory genes identified in the screening
might also improve AAV transduction in vivo. siRNA pools
targeting the mouse orthologs of the top 10 inhibitory genes,
formulated with a commercial cationic lipid-based transfection
reagent, were administered to 1-mo-old mice by portal vein
injection together with an ssAAV8 vector encoding EGFP
(ssAAV8-ApoE/hAAT-EGFP; 5 × 1010 vg; Fig. 5A). Serotype 8
was selected for its superior performance in the liver compared
with AAV2 (3, 34); EGFP expression was driven by the ApoE/
hAAT promoter, which does not undergo transcriptional
silencing over time in the liver (35). Analysis of liver EGFP
fluorescence at 10 d after injection indicated a significant in-
crease in the levels of transduction of the ssAAV8-ApoE/hAAT-
EGFP vector, when coinjected with siRNAs against the top 10
inhibitory genes (Fig. 5 B and C and Fig. S7). This increase in
transduction was widespread throughout the liver, in particular,
in the pericentral vein areas, which are common AAV8 trans-
duction target regions following portal injection in mice (36)
(Fig. 5B and Fig. S7). Real-time, quantitative (q)RT-PCR quanti-
fication of the levels of EGFP mRNA correlated with the extent of
EGFP expression in the analyzed livers (Fig. 5 C and D).
The effect of siRNAs against two genes that induce DNA
damage (SETD8 and CASP8AP2) and three genes that have no
implications on DNA damage [trophinin-associated protein (tastin)
(TROAP), polyhomeotic homolog 3 (Drosophila) (PHC3), and
Retbindin (RTBDN)] was also analyzed at 5 wk after injection.
A significant increase of AAV transduction was also observed
at this time point (Fig. 5 E and F and Fig. S8), indicating stable
AAV transduction. Of note, the siRNA sequences used for
these in vivo experiments were designed to target the mouse
orthologs of the top 10 inhibitory genes. Efficacy of the mouse
siRNAs further confirms the specificity of the observed effects
and the inhibitory function of the identified genes on AAV
transduction.
Discussion
Viral vectors based on AAV have gained increasing popularity
because of several favorable characteristics, including an excel-
lent safety profile, no inflammatory response, prolonged trans-
gene expression, relative genetic simplicity, and high efficiency
of transduction of postmitotic tissues in vivo. Nonetheless, it
has become evident that significant improvements need to be
achieved before attaining broader clinical application. Given the
molecular simplicity of AAV vector particles, all of the determ-
inants of permissivity to vector transduction appear to reside
among the molecular features of the host cell.
To our knowledge, this study is the first to address this issue on
a genome-wide scale, using an unbiased RNAi screening strategy
(18,120 human target genes). By performing a systematic high-
throughput siRNA primary screening based on luciferase gene
expression, followed by an image-based secondary screening to
quantify the fraction of AAV-transduced cells, we identified two
sets of genes with a strong effect on AAV2 transduction, in-
cluding 710 negative and 414 positive regulators. The fact that
the top 10 genes that restrict AAV2 transduction are also active
on other serotypes indicates that the major processes restricting
AAV transduction are most likely subsequent to cell attachment
and vector entry.
The number of cellular factors restricting AAV transduction
was unexpectedly high (1124, 6.2%). Additionally, there was no
apparent homogeneity of function among these factors, except
that most fitted into the categories related to cell cycle regulation
Fig. 4. Cellular DNA damage is a major determinant of AAV
transduction. (A) Effect of knockdown of genes affecting AAV
transduction on cellular DNA damage, detected by the pres-
ence of ɣ-H2AX foci. siRNA pools targeting the 1,483 genes
selected from the primary screening were tested; 17 of the 968
genes identified as negative regulators of AAV transduction
and 2 of the 515 genes identified as positive regulators in-
duced ɣ-H2AX foci (marked with crosses in the graph). (B) Ef-
fect of the top 10 selected siRNAs on cellular DNA damage and
cell cycle (Right). (Scale bar: 50 μm.) (C) Percentage of HeLa cells
in the different stages of the cell cycle, following treatment with
the top 10 siRNA pools; results are shown as means ± SEM
(n = 3). Cells treated with siRNAs against SETD8, CASP8AP2,
NPAT, CHAF1A, and SF3B1 are significantly different com-
pared with control (P < 0.01). (D) Western blot for proteins
involved in different steps of the cellular DDR pathways, fol-
lowing treatment with the top 10 siRNA pools. (E) Represen-
tative images of cells showing nuclear GFP-LacR foci after
treatment with control siRNA or siRNAs targeting CASP8AP2
and SOX15. (Scale bar: 50 μm.) (F ) Percentage of HeLa cells
presenting GFP-LacR nuclear foci, following treatment with the
top 10 siRNA pools. GFP-LacR foci correlate with efficient ssAAV
to dsAAV genome conversion. Results are shown as means ±
SEM (n = 3). ***P < 0.001.
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and DNA recombination and repair. Of the five proteins affected by
the most effective siRNAs, SETD8 is a SET domain containing
lysine methyltransferase (37), CASP8AP2 is a component of the
apoptotic machinery (38), SOX15 is a developmental transcrip-
tion factor (39), TROAP is a cell adhesion molecule reported to
mediate blastocyst implantation (40), and NPAT is a cell cycle
progression regulator encoded within the ATM gene (41). This
heterogeneity of function might indicate that AAV transduction
is regulated at multiple levels or that, more likely, the knock-
down of these factors converge into common intracellular sig-
naling pathways. Indeed, we observed that several of the siRNAs
inducing AAV transduction also directly induced cellular DNA
damage and checkpoint activation (in particular, 5 of the top 10
most effective in increasing AAV transduction).
We previously reported that proteins sensing DNA damage, in
particular, the members of the MRN complex and MDC1, re-
strict AAV transduction by directly binding the incoming AAV
genomes (32, 42). Down-regulation of these proteins, as it occurs
along terminal cell differentiation or following RNAi, positively
correlates with increased AAV permissivity both in vitro and
in vivo (33). Based on this evidence, we proposed a model by
which the induction of cellular DNA damage titrates MRN and
other components of the DDR away from the AAV genomes,
thus allowing their proper processing (32). This “titration model”
explains well why the induction of cellular DNA damage,
through treatment of cells with genotoxic agents (e.g., HU, UV
radiation), favors AAV transduction in vitro and in vivo (4, 5).
The current observation that, among the most effective genes
restricting AAV transduction, there is a clear overrepresentation
of genes that once depleted lead to cellular DNA damage is
fully consistent with this model. Importantly, the top-scoring
genes inducing DNA damage and AAV transduction [SETD8;
CASP8AP2; NPAT; chromatin assembly factor 1, subunit A (p150)
(CHAF1A); and WW and C2 domain-containing 2 (WWC2)] act
on different cellular processes and have no direct function on the
DDR pathways.
We also observed a strong correlation between the genes
acting as positive or negative regulators of ssAAV and scAAV
vectors. This suggests that, although scAAV vectors have the
capacity to self-anneal and thus produce ds transcriptional units
more efficiently than conventional ssAAV vectors (24), the major
determinants of transduction appear to impact on other steps of
vector processing; the fact that the genome structure of scAAV
and ssAAV are identical [inverted terminal repeats (ITRs) and
ss–ds junctions at the hairpins are retained] may explain simi-
larities in genome processing and justify the observed correla-
tion. Consistent with this conclusion, recent evidence indicates
that scAAVs are still inhibited by MRN (43), again suggesting
that physical interaction of the vector DNA with the cellular DDR
machinery is a major restriction factor for transduction. In this re-
spect, however, a caveat is that in our experiments, the selection of
candidate genes for scAAV vectors was performed based on the
results of the initial screenings performed with ssAAV vectors.
Thus, we cannot formally exclude the existence of genes that may
have very prominent effects on scAAV while not affecting ssAAV
transduction and have thus escaped detection in our primary
screening.
An RNAi screening aimed at identifying cellular proteins
controlling AAV2 transduction was performed previously by
Wallen et al. in human aortic endothelial cells, using a siRNA
library targeting 5,520 genes (Druggable Genome Library; pools
of three siRNAs per gene) (44). This screening was dominated
by off-target effects (four of the top five siRNAs were attributed
to seed sequence off-targets), rendering the comparison of re-
sults with our study difficult. siRNA library design algorithms,
pooling strategy, and assay conditions are certainly important
factors that contributed to these results; of note, the seed sequence
identified by the authors (nucleotides 2–7; 5′-UGUUUC-3′) was
present in only 1 of the 72,480 siRNAs tested in our study. In our
work, we validated approximately 70% of the 108 tested candidate
genes in deconvolution experiments, with at least two of the four
individual siRNAs tested for each gene recapitulating the pheno-
type of the siRNA pools. In particular, we validated the top 10
genes increasing AAV transduction by both deconvolution ex-
periments and using different sets of siRNAs designed to target
the mouse orthologs of these 10 genes in vivo. These results
argue in favor of a high degree of confidence in the genes identified
in this study.
The observation that the siRNAs targeting each of the top 10
inhibitory genes markedly increased AAV liver transduction has
potential translational value, because it provides proof-of-prin-
ciple that RNAi and, presumably, pharmacological modulation
of the factors identified through this functional genomics ap-
proach can be successfully exploited to improve AAV efficiency
in vivo. The liver itself is an important organ for AAV-targeted
applications, including gene therapy of hemophilia (45) and of
various other inherited disorders (46–48).
In closing, data from this comprehensive large-scale study con-
stitutes a useful resource to further dissect the molecular aspects
of AAV biology and to design strategies aimed at improving the
utilization of AAV vectors in the gene therapy arena.
Materials and Methods
Production and Purification of Recombinant AAV Vectors. All of the AAV
vectors used in this study were generated by the International Centre for
Genetic Engineering and Biotechnology (ICGEB) AAV Vector Unit (AVU)
(www.icgeb.org/avu-core-facility.html) using a dual/triple plasmid cotrans-
fection procedure followed by PEG precipitation and purification through
CsCl2 gradient centrifugations.
Genome-Wide RNAi Screening. The genome-wide human siRNA library
(siGENOME SMARTPool; pools of four siRNAs per gene) targeting 18,120
human genes was obtained from Dharmacon, Thermo Scientific (catalog no.
G-005005). The siRNA library, arrayed on 384-well plates, was transfected into
HeLa cells using a standard reverse transfection protocol, at a final siRNA
Fig. 5. Knockdown of the identified inhibitory genes improves AAV
transduction in vivo. (A) Schematic of the in vivo AAV transduction experi-
ments. (B) Representative images of liver sections of animals treated
with control and selected siRNAs and transduced with AAV8 encoding
EGFP (ssAAV8-ApoE/hAAT-EGFP). siRNA pools formulated with a commercial
transfection reagent were delivered together with ssAAV8-ApoE/hAAT-EGFP
by portal vein injection and analyzed 10 d after injection. (Scale bar: 1 mm.)
(C and E ) EGFP fluorescence intensity levels in tissue samples analyzed at
10 d (C ) or 5 wk (E ) after injection. (D and F ) EGFP mRNA levels in tissue
samples, quantified by qRT-PCR at 10 d (D) or 5 wk (F ) after injection.
Results in C–F are shown as means ± SEM (n = 3). *P < 0.05, **P < 0.01, and
***P < 0.001.
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concentration of 50 nM. Forty-eight hours after transfection, cells were
transduced with a recombinant ssAAV2 vector (ssAAV2-Luciferase; moi: 2,500
vg/cell) encoding for the Firefly luciferase reporter gene; 21 h later, Alamar
Blue (Life Technologies) was added to the culture medium for 3 h. Luciferase
activity (AAV transduction) and cell viability were measure at 72 h after
transfection. For the image-based secondary, siRNA pools were “cherry-
picked” from the genome-wide siRNA library. Image acquisition and analysis
was performed using an ImageXpress Micro automated high-content screen-
ing fluorescence microscope and MetaXpress software (Molecular Devices). All
screenings were performed in duplicate at the ICGEB High-Throughput
Screening Facility (www.icgeb.org/high-throughput-screening.html).
AAV Liver Transduction. CD1 mice were purchased from Charles River Labo-
ratories Italia Srl. Animal care and treatments were conducted in conformity
with institutional guidelines in compliance with national and international
laws and policies (European Economic Community Council Directive 86/609,
Official Journal L 358, 12 December 1987). Juvenile mice (CD1; 1-mo old;
n = 3–5 per group) were injected into the portal vein with a mixture of
transfection reagent (Lipofectamine RNAiMAX) and siRNAs, together with
AAV8-ApoE/hAAT-EGFP (5 × 1010 vg). Animals were killed 10 d or 5 wk after
injection, and livers were analyzed for the percentage of transduced cells
by fluorescent microscopy, or quantification of EGFP expression, by real-
time qPCR.
Detailed procedures and associated references are available in SI Materials
and Methods.
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Cells. HeLa, U2OS, and MRC5 cell lines (ATCC) were main-
tained in DMEM 1 g/L glucose (Life Technologies) supple-
mented with 10% (vol/vol) FBS (Life Technologies) and anti-
biotics, in a 5% (vol/vol) CO2, humidified atmosphere, at 37 °C.
To obtain HeLa-EGFP, HeLa cells seeded on a 10-cm cell
culture dish were transfected with the pEGFP-C1 plasmid
(Clontech) using FuGENE HD Transfection reagent (Prom-
ega). After selection in culture medium with 400 μg/mL G418
(Life Technologies) for approximately 10 d, cells expressing high
levels of EGFP were enriched by FACS sorting and propagated
as a polyclonal cell population. Stock cultures of HeLa-EGFP
(approximately 95% EGFP-positive cells) and HeLa/GFP-LacR
cells were maintained in culture medium supplemented with
200 μg/mL or 400 μg/mL G418, respectively.
Production and Purification of Recombinant AAV Vectors. All of the
AAV vectors used in this study were generated by the ICGEB
AVU (www.icgeb.org/avu-core-facility.html). Briefly, AAV vec-
tors were generated in HEK293 cells, using a dual-plasmid co-
transfection procedure with pDG, pDF5, or pDF6 as helper
plasmids for packaging vector genomes into AAV2, AAV5, and
AAV6 capsids, respectively (49, 50), and a triple-plasmid co-
transfection procedure for packaging into AAV9 capsids (51).
Viral stocks were purified by PEG precipitation from clarified
cell lysates and cell culture supernatant followed by two con-
secutive CsCl2 gradient centrifugations, as described by Ayuso
et al. (52). Full viral particles obtained from the gradient were
extensively dialyzed in PBS and stored in aliquots at −80 °C until
use. Titration of AAV vector particles was performed by real-
time PCR quantification of the number of viral genomes, as
described previously (31); the viral vector preparations used in
this work were based on the AAV2 genome and had titers be-
tween 2.5 × 1010 and 5.5 × 1012 vg/mL. Transgene expression
from all vectors was driven by the CMV IE promoter, with the
exception of ssAAV8-ApoE/hAAT-EGFP, in which EGFP ex-
pression was under the control of the ApoE/hAAT promoter
(33, 35). The plasmid encoding the genome for AAV2LacO.14
was described previously (32) The plasmid encoding the genome
for scAAV2-EGFP was kindly provided by R. J. Samulski
(University of North Carolina, Chapel Hill, NC).
The plasmid used to produce the ΔVP1-ssAAV2 particles was
obtained by site-directed mutagenesis, using the following pri-
mers: ΔVP1 forward, 5′- CAATAAATGATTTAAATCAGGT-
TTGGCTGCCGATGGTTATCTTCC-3′ and ΔVP1 reverse,
5′- GGAAGATAACCATCGGCAGCCAAACCTGATTTAAAT-
CATTTATTG-3′, which introduced a mutation in the start codon
of VP1 protein from ATG to TTG (53); mutation was verified
by sequencing, and absence of VP1 protein was confirmed by
Western blot.
AAV Transduction. Transduction experiments with the different
AAV vectors was performed at moi: 2,500 vg/cell (wild-type
vectors) or 2.5 × 105 vg/cell (ΔVP1-ssAAV2 vectors). Analysis
of AAV transduction was performed at 24 h after vector addition
to the cells.
For the transduction experiments with AAV6 and AAV9, cells
were treated with 50 mU/mL Neuraminidase (Neuraminidase
from Vibrio cholerae; Sigma-Aldrich) for 3 h, before addition of
the vectors.
Genome-Wide RNAi Screening. The genome-wide human siRNA
library (siGENOME SMARTPool; pools of four siRNAs per
gene) targeting 18,120 human genes, was obtained from Dhar-
macon, Thermo Scientific.
For the genome-wide siRNA screening in HeLa cells, siRNAs
were transferred robotically from stock library plates to white 384-
well plates (PerkinElmer); columns 1, 2, 23, and 24 were left
empty for addition of controls (buffer, nontargeting control
siRNA and siRNAs against luciferase and PLK1). siRNAs were
transfected using a standard reverse-transfection protocol, at a
final siRNA concentration of 50 nM. Briefly, the transfection
reagent (Lipofectamine RNAiMAX; Life Technologies) was
diluted in OPTI-MEM (Life Technologies) and added to the
siRNAs arrayed on the 384-well plates; 30 min later, HeLa cells,
suspended in culture medium without antibiotics, were seeded
(2.0 × 103 per well). Forty-eight hours after transfection, cells
were transduced with a recombinant ssAAV2 vector (ssAAV2-
Luciferase; moi: 2,500 vg/cell) encoding for the Firefly luciferase
reporter gene; 21 h later, Alamar Blue (Life Technologies) was
added to the culture medium for 3 h. At 72 h after transfection
(i.e., 24 h after transduction with ssAAV2-Luciferase), Alamar
Blue fluorescence was measured (λexc = 530 nm; λem = 590 nm),
and cells were immediately lysed and analyzed for luciferase
activity. Conditions were optimized to achieve subsaturating
levels of AAV transduction, to allow detection of both positive
and negative regulators. Luciferase activity was measured using
the PJK Beetle juice-glow reagent (PJK GmbH), according to
the manufacturer’s instructions. Alamar Blue and luciferase ac-
tivity were measured using a PerkinElmer Envision multimode
reader (PerkinElmer).
For the image-based secondary screenings, siRNA pools cor-
responding to the 1,483 genes selected from the primary screening
were cherry-picked from siRNA library stock plates and re-
arrayed onto black clear-bottom 384-well plates (PerkinElmer);
to minimize artifacts attributable to edge effects, the two outer
columns and rows were left empty, and controls were added to
columns 12 and 13 of each plate. Transfection was performed as
described above for the genome-wide screening. For the AAV2
transduction experiments, HeLa-EGFP or HeLa cells were
transduced 48 h after siRNA transfection with ssAAV2-DsRed
or scAAV2-EGFP, respectively, at moi: 2,500 vg/cell. Cells were
fixed at 72 h after plating (i.e., 24 h after AAV transduction) and
processed for fluorescence microscopy. For the analysis of DNA
damage in the absence of AAV transduction, HeLa cells were
transfected as described above, fixed 48 h after transfection, and
processed for immunofluorescence.
All screenings were performed in duplicate, at the ICGEB High-
Throughput Screening Facility (www.icgeb.org/high-throughput-
screening.html).
Fluorescence Staining and Immunofluorescence. For the AAV
transduction experiments with ssAAV2-DsRed or scAAV2-EGFP
and for the experiments with AAV2LacO.14, cells were fixed with
4% (wt/vol) paraformaldehyde (PFA) for 15 min, washed with
PBS, and stained with Hoechst 33342 (Life Technologies).
For evaluation of DNA damage, cells were fixed with 4% PFA
for 15 min and permeabilized with 0.5% Triton X-100 in PBS for
10 min, followed by 30 min of blocking in 1% BSA (Roche). Cells
were then incubated for 1 h with a primary antibody for Phospho-
Histone-H2A.X p-Ser139 (ɣ-H2AX) (05-636; 1:500 in blocking
solution; Millipore). Cells were washed with PBS and incubated
for 1 h with an Alexa Fluor-488–conjugated secondary antibody
Mano et al. www.pnas.org/cgi/content/short/1503607112 1 of 9
(Life Technologies) and stained with Hoechst 33342 (Life
Technologies).
Image Acquisition and Analysis. For the image-based secondary
screenings, image acquisition was performed using an ImageXpress
Micro automated high-content screening fluorescence micro-
scope (Molecular Devices) at a 10×magnification; a total of four
images were acquired per wavelength, well, and replicate, cor-
responding to approximately 1,500–2,000 cells analyzed per
condition and replicate. Image analysis was performed using the
Multi-Wavelength Cell Scoring application module implem-
ented in MetaXpress software (Molecular Devices). Quantifi-
cation of cells positive for ɣ-H2AX was performed using the
same methodology, except that nine images were acquired per
well, at a 20× magnification.
For the analysis of single-stranded to double-stranded genome
conversion, image acquisition was performed in a Zeiss LSM-510
confocal laser-scanning microscope at a 63× magnification. Cells
were scored manually for the presence of GFP-LacR foci.
Sections of mouse liver were imaged using an ImageXpress
Micro automated high-content screening fluorescence micro-
scope, at a 4× magnification. Images of large tissue areas (36
images per sample) were obtained by stitching of individual
images, using MetaXpress software; quantification of EGFP in-
tensity in tissue samples was performed using the MetaXpress
software.
Functional Gene Analysis. Functional analysis of the genes identi-
fied in the primary screening as required or inhibitory to AAV
transduction was conducted using Ingenuity Pathway Analysis
software (IPA) (Ingenuity Systems). Datasets were uploaded into
IPA and analyzed for functional enrichment in terms of Molecular
and Cellular Functions, based on the information in the Ingenuity
Knowledge Base. Enrichments were calculated by IPA using
right-tailed Fisher’s exact test; uncorrected P values are shown.
Cell Cycle Analysis. For cell cycle analysis by flow cytometry, cells
were fixed as described above and washed with PBS. DNA
staining was performed by incubating cells with 50 μg/mL pro-
pidium iodide (Sigma) and 0.2 mg/mL RNase A (Sigma) in
buffer H (20 mMHepes, 160 mMNaCl, 1 mM EGTA), for 30 min
at 37 °C. Cells (10,000 cells per experimental condition and
replicate) were analyzed on a FACSCalibur flow cytometer
(Becton Dickinson); analysis of the distribution of the different
phases of cell cycle was performed using the FlowJo software
(Tree Star) with the Dean–Jett–Fox model.
Whole-Cell Protein Extracts and Western Blot. For Western blot
analysis, HeLa cells were seeded in six-well plates (2.0 × 105 per
well). Transfection of siRNA pools was performed using Lipofect-
amine RNAiMAX, at a final siRNA concentration of 50 nM.
Forty-eight hours after siRNA transfection, the cells were
collected in HNNG buffer [15 mM Hepes (pH 7.5), 250 mM
NaCl, 1% Nonidet P-40, 5% (vol/vol) glycerol, 1 mM PMSF] sup-
plemented with 25 mM NaF, 10 mM β-glycerophosphate, 0.2 mM
sodium orthovanadate, and protease inhibitors (Roche). Protein
concentration was determined by the colorimetric bicinchoninic
acid protein assay (Thermo Scientific) in a Envision multimode
reader. Protein samples (15 μg) were separated in 8–12% SDS/
PAGE minigels and transferred onto nitrocellulose membranes
(GE Healthcare). Membranes were blocked in 5% (wt/vol) BSA
in TBST [50 mM Tris·HCl (pH 7.4), 200 mM NaCl, 0.04%
Tween 20] at room temperature for 2 h; membranes for P-NBS1
were blocked overnight in 5% (wt/vol) nonfat dry milk; immuno-
blots for NBS1, P-CHK1, ATM, CHK1, α-tubulin and HSP70 were
blocked in 5% nonfat dry milk at room temperature for 2 h. The
following primary antibodies were used: SETD8 (C18B7; 1:500;
Cell Signaling), NPAT (ab70595; 1:500; Abcam), Phospho-ATM
p-Ser1981 (P-ATM) (4526; 1:500 in 5% BSA; Cell Signaling), ATM
(2873; 1:500 in 5% BSA; Cell Signaling), Phospho-NBS1 p-Ser343
(P-NBS1) (NB100-92610; 1:500 in 5% nonfat dry milk; Novus
Biologicals), NBS1 (NB100-143; 1:3,000 in 5% nonfat dry milk;
Novus Biologicals), Phospho-CHK1 p-Ser345 (P-CHK1) (2348;
1:500 in 5% BSA; Cell Signaling), CHK1 (2360; 1:1,000 in 5%
nonfat dry milk; Cell Signaling) and α-tubulin (T5168; 1:10,000 in
5% nonfat dry milk; Sigma). For analysis of AAV vector particles,
an anti-AAVVP1/VP2/VP3 mouse monoclonal antibody was used
(B1; 1:200; Progen Biotechnik). Secondary antibodies coupled
to horseradish peroxidase (Santa Cruz Biotechnology) were used.
Signals were detected using the ECL chemiluminescence system
(Amersham).
HU (Sigma) was used a positive control in these experiments;
where indicated, cells were incubated overnight with 1 mM HU,
before cell fixation.
AAV Liver Transduction. Juvenile mice (CD1; 1-mo old; n = 3–5 per
group) were injected into the portal vein with a mixture of
transfection reagent (Lipofectamine RNAiMAX) and each of
the siRNA pools against the top 10, or a nontargeting control
(1:1 transfection reagent:siRNA mixture, 25 μL), together with
AAV8-ApoE/hAAT-EGFP at a dose of 5 × 1010 vg (25 μl); a
volume of 50 μL per animal was injected slowly using a U-100 in-
sulin syringe. Animals were killed 10 d or 5 wk after injection to
evaluate AAV transduction. Livers were collected, carefully divided
in lobes, and a piece of every lobe was processed for evaluation of
the percentage of transduced cells by fluorescent microscopy, or
quantification of EGFP expression, by real-time qPCR.
For fluorescent microscopy, liver tissue was fixed in 4% PFA
overnight at 4 °C, cryoprotected in 30% (wt/vol) sucrose overnight at
4 °C, and then frozen at −20 °C. Liver sections (5 μm) were imaged
using an ImageXpress Micro automated high-content screening
microscope equipped with a 4× objective. Nuclei were identified by
counter staining sections with DAPI (Life Technologies); slides
were mounted in Vectashield mounting medium (Vector Labs).
RNA Isolation and Quantitative Real-Time PCR.Total RNA from liver
tissue or cells treated with the different siRNA pools was isolated
using TRIzol (Life Technologies). mRNA was reverse-transcribed
using random primers (Life Technologies) and M-MLV reverse
transcriptase (Life Technologies). Real-time quantitative analysis
was performed using the iQ SYBRGreen Supermix or iQ Supermix,
in a CFX96 Real-Time system (Bio-Rad). The following primers
were used: GFP-forward, 5′-TCAAGGAGGACGGCAACATC-3′;
and GFP-reverse, 5′-TTGTGGCGGATCTTGAAGTTC-3′. For
the evaluation of gene knockdown, analysis was performed
48 h after siRNA transfection, using the following Taqman
assays (Life Technologies): SETD8, Hs01029945_m1; CAS-
P8AP2, Hs01594281_m1; SOX15, Hs00199511_m1; TROAP,
Hs00193896_m1; NPAT, Hs00159638_m1; PHC3, Hs00227887_m1;
CHAF1A, Hs00193920_m1; SF3B1, Hs00961640_g1; RTBDN,
Hs01564130_m1; and WWC2, Hs00420500_m1. Results were
normalized to GAPDH [TaqMan assays 4352339E (mouse) and
4326317E (human); Life Technologies]. Fold changes were de-
termined using the 2−ΔΔCt method.
Statistical Analysis. Unless otherwise indicated, all data are pre-
sented as means ± SEM. Statistical analysis was carried out using
Prism Software (GraphPad). For statistical comparison of two
groups, two-tailed Student’s t test was used. A value of P < 0.05
was considered significant.
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Fig. S1. Genome-wide siRNA screening for AAV transduction. (A) Representative images of HeLa cells transfected with control or a toxic siRNA (siRNA against
PLK1), at 48 h after transfection. (Scale bar: 100 μm.) (B) Correlation between the two replicates of the primary screening, using a genome-wide library of siRNA
targeting 18,120 genes. Results are shown as fold change of AAV transduction normalized to cell viability, in log2 scale; Spearman rank correlation coefficient
between the two replicates is shown. (C) Summary of screening controls, included in all of the screening plates. (Left) Effect of control siRNAs on luciferase
activity. (Right) Effect of control siRNAs on cell viability. Whiskers in the graphs represent minimum and maximum.
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Fig. S2. Effect of siRNAs on AAV transduction. Representative images of HeLa-EGFP cells treated with the 10 siRNA pools that increased (upper images) or
decreased (lower images) AAV transduction more efficiently in the primary screening. HeLa-EGFP cells were transfected with the siRNAs and transduced 48 h
later with ssAAV2-DsRed, at moi: 2,500 vg/cell; AAV transduction was analyzed after 24 h. (Scale bar: 100 μm.)
Fig. S3. Functional analysis of genes identified in the genome-wide siRNA screening. (A and B) Functional categories enriched among the 968 genes identified
in the primary screening as negative regulators of AAV transduction (A) or 515 genes identified as positive regulators (B). Enrichment analysis was performed
using IPA software; the 12 most enriched categories are shown. Red line represents P = 0.05.
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Fig. S4. Deconvolution of selected siRNA pools. (A and B) Effect of individual siRNAs on AAV transduction. The four individual siRNAs corresponding to the
siRNA pools exhibiting the strongest effects were tested: 68 inhibitory genes (A); 40 required genes (B). HeLa cells were transfected with the siRNAs and
transduced 48 h later with ssAAV2-luciferase, at moi: 2,500 vg/cell; AAV transduction was analyzed after 24 h. Heat map represents fold change of AAV
transduction normalized to control siRNA. (C) Percentage of siRNA pools validated with zero, one, two, three, or four of the four siRNAs tested per gene.
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Fig. S5. Efficiency of knockdown by siRNAs. (A) Effect of the siRNA pools against the top 10 siRNAs increasing transduction in the primary screening on target
transcript levels. Results were normalized to GAPDH and are shown as means ± SEM (n = 3). *P < 0.05 and ***P < 0.001. (B) Western blot analysis of the effect
of the siRNA pools against SETD8 and NPAT on the protein levels. Asterisk on upper blot denotes a nonspecific band, as per the antibody datasheet; tubulin
was used as a loading control.
Fig. S6. Efficiency of siRNAs on δVP1 AAV transduction. Effect of the siRNA pools against the top 10 siRNAs increasing transduction in the primary screening
on the transduction mediated by δVP1-ssAAV2 particles. The δVP1-ssAAV2 particles are strongly impaired in intracellular trafficking because of the lack of the
capsid protein VP1. Results are shown as means ± SEM (n = 3). *P < 0.05 and **P < 0.01.
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Fig. S7. Effect of siRNAs on AAV transduction in vivo. Representative images of liver sections of animals treated with control and selected siRNAs (top 10
siRNAs increasing transduction in the primary screening) and transduced with AAV8 encoding EGFP (ssAAV8-ApoE/hAAT-EGFP). siRNA pools formulated with a
commercial transfection reagent were delivered together with ssAAV8-ApoE/hAAT-EGFP (5 × 1010 vg) by portal vein injection and analyzed 10 d after injection.
(Scale bar: 1 mm.)
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Fig. S8. Effect of siRNAs on AAV transduction in vivo. Representative images of liver sections of animals treated with control and selected siRNAs from the top
10 siRNAs increasing transduction in the primary screening and transduced with AAV8 encoding EGFP (ssAAV8-ApoE/hAAT-EGFP). siRNAs targeting two
proteins that induce DNA damage (SETD8 and CASP8AP2) and three proteins that have no implications to DNA damage (TROAP, PHC3, and RTBDN) were
selected. siRNA pools formulated with a commercial transfection reagent were delivered together with ssAAV8-ApoE/hAAT-EGFP (5 × 1010 vg) by portal vein
injection and analyzed 5 wk after injection. (Scale bar: 1 mm.)
Table S1. Effect of selected siRNAs on AAV transduction
Gene identification no. Gene symbol Gene name Fold change AAV2
387893 SETD8 SET domain containing (lysine methyltransferase) 8 51.4
9994 CASP8AP2 caspase 8-associated protein 2 30.2
6665 SOX15 SRY (sex-determining region Y)-box 15 27.0
10024 TROAP trophinin-associated protein (tastin) 25.1
4863 NPAT nuclear protein, ataxia-telangiectasia locus 23.6
80012 PHC3 polyhomeotic homolog 3 (Drosophila) 23.1
10036 CHAF1A chromatin assembly factor 1, subunit A (p150) 20.9
23451 SF3B1 splicing factor 3b, subunit 1, 155 kDa 20.5
83546 RTBDN Retbindin 19.3
80014 WWC2 WW and C2 domain-containing 2 19.2
9426 CDY2A chromodomain protein, Y-linked, 2A −11.7
85319 BAGE2 B melanoma antigen family, member 2 −10.6
1147 CHU.K. conserved helix–loop–helix ubiquitous kinase −10.1
353135 LCE1E late cornified envelope 1E −9.8
7286 TUFT1 tuftelin 1 −9.7
79668 PARP8 poly(ADP ribose) polymerase family, member 8 −9.4
219557 C7orf62 chromosome 7 ORF 62 −9.1
29119 CTNNA3 catenin (cadherin-associated protein), α3 −9.1
64755 C16orf58 chromosome 16 ORF 58 −9.0
347732 CATSPER3 cation channel, sperm-associated 3 −8.9
Average results from the two screening replicates for the top 10 negative and positive regulators of AAV transduction.
Dataset S1. Genome-wide siRNA screening for AAV transduction: primary screening data
Dataset S1
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Dataset S2. Percentage of DsRed- and EGFP-positive cells after treatment with siRNAs against the 1,483 genes selected from the
primary screening
Dataset S2
Dataset S3. Effect of the knockdown of the 1,483 selected genes on the percentage of cells transduced with ssAAV2-DsRed or
scAAV2-EGFP vectors
Dataset S3
Dataset S4. Effect of knockdown of the 1,483 selected genes affecting AAV transduction on the percentage of cells presenting cellular
DNA damage, revealed by the presence of ɣ-H2AX foci
Dataset S4
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